Preferences help
enabled [disable] Abstract
Number of results
2013 | 8 | 3 | 354-357
Article title

Urine saturation and promoter/inhibitor parameters and ratios in renal stone disease caused by ceftriaxone

Title variants
Languages of publication
During ceftriaxone treatment of subdural empyema caused by Streptococcus intermedius urinary and biliary stones were noticed. Increased levels of urinary calcium excretion were detected during ongoing treatment in comparison with 2 months check-up. There were no significant changes in the promoter/inhibitor urolithiasis parameters, oxalate, citrate, urate, cistine, glycosaminoglycans or their ratios. Urine saturation was calculated using EQUIL 2 computer programme (calcium oxalate, brushite) and it was normal. Probable trigger for the ceftriaxone/calcium hydroxy carbonate phosphate mixture of stones was a critical boost of solubility products caused by ceftriaxone treatment and phospnate urine content with a subsequent large-scale spontaneous precipitation of crystals.
Physical description
1 - 6 - 2013
17 - 4 - 2013
  • Department for Pediatric Nephrology, University Children’s Hospital Zagreb, Zagreb School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia
  • Department for Pediatric Infectious diseases, School of Medicine, Zagreb University, Zagreb, Croatia
  • Department for Physical chemistry, Institute „Ruđer Bošković“, Bijenička cesta 54, 10000, Zagreb, Croatia
  • Department of Anesthesiology and Intesive Care, University Clinical Centre Zagreb, Zagreb, Croatia
  • Department for Pediatric Nephrology, University Children’s Hospital Zagreb, Zagreb School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia
  • Department for Pediatric Nephrology, University Children’s Hospital Zagreb, Zagreb School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia
  • Department for Pediatric Nephrology, University Children’s Hospital Zagreb, Zagreb School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia
  • [1] Schaad UB., Wedgwood-Krucko J., Tschaeppler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet, 1988, 8625, 1411–1413[Crossref]
  • [2] de Moor RA., Egberts AC., Schröder CH. Ceftriaxone associated nephrolythiasis and biliary pseudolithiasis. EUR J Pediatr, 1999, 158, 975–977[Crossref]
  • [3] Bor O., Dinleyici EC., Kebapci M., Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int, 2004, 46, 322–324[Crossref]
  • [4] Acun C., Erdem LO., Söğüt A., Erdem CZ., Tomaç N., Gündoğdu S., et al. Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study., Ann Trop Pediatr, 2004, 24, 25–31[Crossref]
  • [5] Gargollo PC., Barnewolt CE., Diamond DA. Pediatric ceftriaxone nephrolythiasis. J Urol, 2005, 173, 577–578[Crossref]
  • [6] Mohkam M., Karimi A., Gharib A., Daneshmand H., Khatami A., Ghojevand N., et al. Ceftriaxone associated nephrolythiasis: a prospective study in 284 children. Pediatr nephrol, 2007, 22, 690–694[WoS]
  • [7] Avci Z., Koktener A., Uras N., Catal F., Karadag A., Tekin O., et al. Nephrolythiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child, 2004, 89, 1069–1072[Crossref]
  • [8] Karlizcek SB., Döring S., Vogt S., et al.Ceftriaxone-associated nephrolythiais. Two case reports. Monatsschr Kinderheilkd, 1996, 144, 702–706
  • [9] Kimata T., Kaneko K., Takahashi M., Hirabayashi M., Shimo T., Kino M. Increased urinary calcium excretion caused by ceftriaxone: possible association with urolythiasis. Pediatr nephrol, 2012, 27, 605–609[Crossref][WoS]
  • [10] Lozanovski VJ., Gucev Z., Avramoski VJ., Kirovski I., Makreski P., Tasic V. Ceftriaxone associated urolithisis in a child with hypercalciuria. Hippokratia, 2011, Apr–Jun 15(2),181–183
  • [11] Milošević D., Batinić D. Blau N., Konjevoda P., Štambuk N., Votava-Raić A., et al.Determination of urine saturation with computer program Equil 2 as a method for estimation of the risk of urolithiasis. J Chem Inf Comput Sci, 1998, 38(4), 646–650[Crossref]
  • [12] Batinić D., Milošević D., Blau N., Konjevoda P., Štambuk N., Barbarić V., et al. of the stone promoters/inhibitors ratios in the estimation of the risk of urolithiasis. J Chem Comput Sci, 2000, 40(3), 607–610 [Crossref]
  • [13] Werness P., Brown CM., Smith LH., Finlayson B., EQUIL II: a BASIC computer program for the calculation of urinary saturation. J Urol, 1985, 134, 1242–1244
  • [14] Witten IH., Frank E. Data mining:practical machine learning tools and techniques with Java implementations. Morgan Kaufman: San Francisco, 2000.
  • [15] Milošević D., Batinić D., Konjevoda P., Blau N., Štambuk N., Nižić L.j, et al. of calcium, oxalate, and citrate interaction in idiopathic calcium urolithiasis in children. J Chem Inf Comput Sci, 2003, 43(6), 1844–1847[Crossref]
  • [16] Chutipongtanate S. and Thongboonkerd V. Ceftriaxone crystallization and it potential role in kidney stone formation. Biochem Biophys Res Commun., 2011 Mar, 406(3), 396–402[Crossref]
  • [17] Reid DG., Jackson GJ., Duer MJ., Rodgers AL. Apatite in kidney stones is a molecular composite with glycosaminogycans and proteins: evidence from nuclear magnetic resonance spectroscopy, and relevance to Randall’s plaque, pathogenesis and prophylaxis. J Urol, 2011 Feb, 185(2), 725–730[WoS][Crossref]
  • [18] Hesse A. and Heimbach D. Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol, 1999 Oct, 17(5), 308–315[Crossref]
  • [19] Battino BS., DeFOOR W., Coe F., Tackett L., Erhard M., Wacksman J., Sheldon CA., Minevich E. Metabolic evaluation of children with urolithiasis: arer adult references for supersaturation appropriate?. J Urol, 2002 Dec, 168(6), 2568–2571[Crossref]
  • [20] Patzer L., van’t Hoff W., Shah V., Halson P., Kasidas GP., Colin S., de Bruyn R., Baratt TM., Dillon MJ. Urinary supersaturation of calcium oxalate and phosphate in patients with X-linked hypophosphatemic rickets and in healthy school children. J Pediatr, 1999 Nov, 135(5), 611–617[Crossref]
  • [21] Shiffman M., Keith FB., Moore EW. Pathogenesis of seftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology, 1990 Dec, 99(6), 1772–1776
  • [22] Malsy A. and Bohner M. Brushite conversion into apatite. European Cells and Minerals Vol, 10. Suppl. 1, 2005, (page 28)
  • [23] Asplin J., Parks J., Lingeman J., Kahnoski R., Mardis H., Lacey S., Goldfarb D., Grasso M., Coe F. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol, 1998 Jun, 159(6), 1821–1825[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.